Open AccessBullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report
Author(s) -
Kasamatsu Hiroshi,
Chino Takenao,
Oyama Noritaka,
Nakaya Takakiyo,
Hasegawa Minoru
Publication year - 2021
Publication title -
journal of cutaneous immunology and allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.127
H-Index - 1
ISSN - 2574-4593
DOI - 10.1002/cia2.12162
Subject(s) - bullous pemphigoid , dipeptidyl peptidase 4 inhibitor , autoantibody , dipeptidyl peptidase , medicine , culprit , dipeptidyl peptidase 4 , pemphigoid , saxagliptin , antibody , titer , linagliptin , diabetes mellitus , sitagliptin , gastroenterology , pharmacology , type 2 diabetes , immunology , endocrinology , chemistry , biochemistry , enzyme , myocardial infarction
The present paper reports a case of bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 inhibitor omarigliptin, by which serum IgG autoantibodies are directed against BP180‐NC16a domain. Our present case had non‐inflamed phenotype, and the relatively higher antibody titer was prolonged even after withdrawal of the culprit omarigliptin.